



# CLINICAL APPLICATION OF CAR T CELLS

NON-CME INDUSTRY SESSIONS | Novel Cell Therapies and Assays

Memorial Sloan Kettering Cancer Center will not be offering CME credits for the optional non-CME industry sessions.

## Invited Course Faculty (Industry Session)

### Mauro Avanzi, MD, PhD

Director, Medical Research  
Kite Pharma  
Los Angeles, CA

### Sharon Benzeno, PhD, MBA

SVP Research and Business Development  
Adaptive Biotechnologies  
Seattle, WA

### Stephanie Farnia, MPH

Director, Clinical Value  
Blue Cross Blue Shield Association  
Madison, WI

### Joseph A. Fraietta, PhD

Director, Solid Tumor Immunotherapy Laboratory  
Center for Advanced Cellular Therapeutics  
University of Pennsylvania  
Philadelphia, PA

### William Go, MD, PhD

Senior Vice President, Development  
A2 Biotherapeutics  
Agoura Hills, CA

### Christopher Haqq, MD, PhD

Chief Scientific Officer  
Atara Biotherapeutics  
San Francisco, CA

### Aisha N. Hasan, MD

Clinical Development Head- Cell and Gene Therapy  
GlaxoSmithKline Oncology  
Brentford, United Kingdom

### Susie Jun, MD, PhD

Chief Development Officer  
Allogene Therapeutics, Inc.  
South San Francisco, CA

### Cheng Liu, PhD

Founder and CEO  
Eureka Therapeutics  
Emeryville, CA

### Bruce McCreedy, PhD

Senior Vice President, Immuno-Oncology  
Precision BioSciences, Inc.  
Durham, NC

### Fyodor Urnov, PhD

Deputy Director  
Altius Institute for Biomedical Sciences  
Seattle, WA

### Loïc Vincent, PhD

Head of Cell Therapy Discovery  
Takeda Pharmaceuticals International Co.  
Cambridge, MA

### Louisa Wirthlin

Senior Clinical Applications Manager  
Miltenyi Biotec  
Bergisch Gladbach, Germany

### Travis Young, PhD

VP Biologics  
Calibr - The California Institute for  
Biomedical Research  
La Jolla, CA

## MSK Course Faculty (Industry Session)

### Yashodhara Dash, MD, PhD, MBA

Senior Director, Research and Technology Management

### Jae Park, MD

Assistant Attending  
Leukemia Service

Join the conversation with @MSKCME

 #MSKCART19

## Thursday, March 14

### 6. Optional Non-CME Industry Session\* (4:30 PM - 6:00 PM - Auditorium)

MODERATORS: Yashodhara Dash, MD, MBA, PhD and Aisha N Hasan, MD

4:30 PM	<b>CAR Intellectual Property - Collaborations and Licensing</b> Yashodhara Dash, MD, MBA, PhD
4:40 PM	<b>Considerations for Engineering Efficacy Enhanced Next Generation T cell Products</b> Aisha N. Hasan, MD
4:50 PM	<b>Takeda's Differentiated Cell Therapy Approach: Helping Patients Through Collaboration</b> Loïc Vincent, PhD
5:00 PM	<b>Development of an Allogeneic EBV CAR T Platform</b> Christopher Haqq, MD, PhD
5:10 PM	<b>TruTCR™ Drug Discovery Platform — High-Throughput Identification of Neoantigen-specific TCRs</b> Sharon Benzeno, PhD, MBA
5:20 PM	<b>ALLO-501: The First Allogeneic CAR-T Therapy for Non-Hodgkin Lymphoma in Clinical Trial</b> Susie Jun, MD, PhD
5:30 PM	<b>Development of ARTEMIS™ Antibody-TCR (AbTCR) Expressing T cells Against Solid and Hematological Malignancies with the Potential to Eliminate CRS Risks</b> Cheng Liu, MD, PhD
5:40 PM	<b>Control of Cellular Immunotherapy</b> Travis Young, PhD
5:50 PM	<b>Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety And Efficacy Of Zuma-1</b> Mauro Avanzi, MD, PhD
6:00 PM	Adjourn

## Friday, March 15

### 12. Optional Non-CME Industry Session\* (5:00 PM - 5:30 PM - Auditorium)

MODERATORS: Jae Park, MD and Joseph A. Fraietta, PhD

5:00 PM	<b>Challenges of Engineered Cell Therapy in Solid Tumors</b> William Go, MD, PhD
5:06 PM	<b>ePECS: Ex-vivo Pleural Effusion Culture System for Investigating IO Agents</b> Stefan Kiesgen, PhD
5:12 PM	<b>CAR-T Manufacturing with Miltenyi Biotec</b> Louisa Wirthlin, BS
5:18 PM	<b>Calibration Of CAR Activation Potential Directs Therapeutic Potency</b> Judith C. Feucht, MD
5:24 PM	<b>TBA</b> TBA
5:30 PM	Adjourn

**\*Memorial Sloan Kettering Cancer Center will not be offering CME credits for the optional non-CME industry sessions.**